Don’t compromise care for convenience. The DRE is still relevant.

Reintroduce Select mdx into your practice risk-free

Contact your local representative today to learn how.

*required

Don’t skip the DRE. 5 reasons to adapt your workflow.

It’s in the guidelines.

Both AUA and NCCN Guidelines recommend performing a DRE on men with an elevated PSA.3

Studies show it’s relevant.

A study as recent as November of 2023 demonstrated the diagnostic accuracy of DRE to be over 63% in patients with suspected clinically significant prostate cancer.4

It’s cost effective.

Medicare covers a DRE and PSA test for men over 50 as part of routine annual prostate cancer screening.5

Increases patient confidence with a thorough workup.

Performing a DRE is part of the recommended screening for early detection of prostate cancer and represents to the patient that his physician is being thorough in his exam and evaluating the patient’s risk for prostate cancer.

Top urology centers are still performing them.

Cedars Sinai, Cleveland Clinic and Johns Hopkins are among many top urology centers performing DREs as part of their prostate cancer screening process.6

Unleash the predictive power of Select mdx

99% NPV for GS≥8 | 95% NPV for GS≥71

No PSA level restrictions

Outperformed PCA32

Included in the NCCN guidelines & covered by Medicare3

Patient First Promise and Satisfaction Guarantee

We believe no patient should be denied access to powerful diagnostic insights due to financial constraints. That’s why we are committed to making our tests accessible and affordable through our Patient First Promise.

Every patient, regardless of insurance status, is eligible to apply for our financial assistance program. And with our Satisfaction Guarantee, you can recommend mdxhealth tests with full confidence. If you are unsatisfied with how we handle any patient billing matter, we will refund the entire cost – no questions asked.

References

1 Haese A, et al. Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy. Journal of Urology 2019.
2 Hendriks RJ, et al. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. The Prostate 2017.
3 https://emedicine.medscape.com/article/2259453-overview
4 Ying Y, et al. Value of digital rectal examination in patients with suspected prostate cancer: a prospective cohort analysis study. Translational andrology and urology 2023.
5 https://www.medicare.gov/coverage/prostate-cancer-screenings
6 https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/prostate-cancer-screening; https://my.clevelandclinic.org/health/diagnostics/24212-digital-rectal-exam; https://www.cedars- sinai.org/programs/urology/specialties/general/digital-rectal-exam.html